Supplementary Materials

A Propensity Score Matched Analysis of Superparamagnetic Iron Oxide versus Radioisotope Sentinel Node Biopsy in Breast Cancer Patients after Neoadjuvant Chemotherapy

Zuzanna Pelc [1,*], Magdalena Skórzewska [1], Maria Kurylcio [1], Tomasz Nowikiewicz [2], Radosław Mlak [3], Katarzyna Sędłak [1], Katarzyna Gęca [1], Karol Rawicz-Pruszyński [1], Wojciech Zegarski [2], Wojciech P. Polkowski [1] and Andrzej Kurylcio [1]

[1] Department of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080 Lublin, Poland; magdalena.skorzewska@umlub.pl (M.S.); m.kurylcio@gmail.com (M.K.); sedlak.katarz@gmail.com (K.S.); kasiaa.geca@gmail.com (K.G.); karolrawiczpruszynski@uml.edu.pl (K.R.-P.); wojciechpolkowski@umlub.pl (W.P.P.); andrzej.kurylcio@umlub.pl (A.K.)

[2] Department of Clinical Breast Cancer and Reconstructive Surgery, Oncology Center, Prof. Lukaszczyk Memorial Hospital, Romanowskiej 2 St., 85-796 Bydgoszcz, Poland; tomasz.nowikiewicz@cm.umk.pl (T.N.); zegarskiw@cm.umk.pl (W.Z.)

[3] Department of Human Physiology, Medical University of Lublin, Radziwiłłowska 11 St., 20-080 Lublin, Poland; radoslaw.mlak@gmail.com

* Correspondence: zuzanna.torun@gmail.com; Tel.: +48-81-53-18-126

Table S1. Influence of selected demographic and clinical variables on the efficacy of LNs evaluation in the RI and SPIO groups.

Variable	RI (n = 62) SLNs Evaluation Efficacy		p^a lub OR [95%CI]	SPIO (n = 62) SLNs Evaluation Efficacy		p^a lub OR [95%CI]
	<3 evaluated LNs	>=3 evaluated LNs	p^b	<3 evaluated LNs	>=3 evaluated LNs	p^b
Age (lyears) Median [interquartile range]	55.5 [49–62]	47.5 [43–60]	0.0618	52 [43–59]	55 [43.5–62.5]	0.6674
Weight (kg) Median [interquartile range]	71 [60–78]	69 [62–73]	0.5349	69 [56–85]	67 [60.5–77]	0.7680
BMI Median [interquartile range]	25.94 [23.19–28.76]	25.53 [23.46–29.69]	0.7781	25.90 [21.60–30.12]	25.97 [21.91–28.30]	0.9798
BMI Underweight or Healthy body weight	13 (48.1%)	14 (51.9%)	0.98 [0.36–2.68] 0.9736	6 (25%)	18 (75%)	1.25 [0.37–4.19] 0.7176
Overweight or Obese (classes 1–3)	17 (48.6%)	18 (51.4%)		8 (21.1%)	30 (78.9%)	

Tumor highest diameter (mm)	16 [13–31]	22 [13–30]	0.7969	25 [19–34]	22 [13–30]	0.3580
ypT 0 1 or 2	17 (47.2%) 13 (50%)	19 (52.8%) 13 (50%)	0.89 [0.33–2.45] 0.8290	8 (22.9%) 6 (22.2%)	27 (77.1%) 21 (77.8%)	1.04 [0.31–3.45] 0.9527
ypN Negative Positive	27 (47.4%) 3 (60%)	30 (52.6%) 2 (40%)	0.60 [0.09–3.87] 0.5910	13 (22.8%) 1 (20%)	44 (77.2%) 4 (80%)	1.18 [0.12–11.52] 0.8857
Biological subtype of cancer A, B1, B2, HER2+ TN	21 (47.7%) 9 (50%)	23 (52.3%) 9 (50%)	0.91 [0.30–2.73] 0.8709	11 (25%) 3 (16.7%)	33 (75%) 15 (83.3%)	1.67 [0.40–6.86] 0.4792
Biological subtype of cancer A, B1, B2, TN HER2+	27 (49.1%) 3 (42.9%)	28 (50.9%) 4 (57.1%)	1.29 [0.26–6.29] 0.7564	13 (23.6%) 1 (14.3%)	42 (76.4%) 6 (85.7%)	1.86 [0.20–16.87] 0.5824
Response to NAC* No response Response	9 (47.4%) 21 (48.8%)	10 (52.6%) 22 (51.2%)	0.94 [0.32–2.78] 0.9150	6 (23.1%) 8 (22.2%)	20 (76.9%) 28 (77.8%)	1.05 [0.31–3.50] 0.9367

RI—radioisotope, SPIO—superparamagnetic iron oxide, OR—odds ratio, pa—chi-square test result, pb—odds ratio test result, SLNs—sentinel lymph nodes, BMI—body mass index, ypT—post neoadjuvant therapy pathological tumor categorization, ypN—post neoadjuvant therapy pathological nodal categorization, A—luminal A, B1—luminal B human epithelial receptor-negative, B2—luminal B human epithelial receptor-positive, HER2+—human epithelial receptor-positive, TN – triple-negative, *—statistically significant result, ^—a trend into statistically significant result.